Stifel Downgrades Gemini Therapeutics (GMTX) to Hold, Slashes Price Target to $2, Cites Lower Probability of Success for GEM103 and Higher Overall Risks

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/13/2026

1. CSCO
2. CBRS
3. COHR
4. SPY
5. STUB
6. EAT
7. BTGO
8. NVDA
9. WYFI
10. ARX

Go back to Stifel Downgrades Gemini Therapeutics (GMTX) to Hold, Slashes Price Target to $2, Cites Lower Probability of Success for GEM103 and Higher Overall Risks

Gemini Therapeutics (GMTX) Issues Corporate Update

February 28, 2022 8:32 AM EST

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today provided a corporate update announcing a leadership transition, strategic evaluation and corporate restructuring.

The Board of Directors has appointed Georges Gemayel, Ph.D., the Companys current Executive Chair, as interim President and Chief Executive Officer to succeed Jason Meyenburg, who has transitioned from his roles as President, CEO and Director and will continue to serve as an advisor to the Company.

Additionally, the Company has initiated a process to evaluate strategic... More